Arvelle Therapeutics
Acquisition in 2021
Arvelle Therapeutics GmbH is a biopharmaceutical company headquartered in Zug, Switzerland, founded in 2019. The company is dedicated to developing and commercializing innovative treatments for patients suffering from central nervous system (CNS) disorders. Its primary focus is on cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients experiencing focal seizures. Through its efforts, Arvelle Therapeutics seeks to enhance the quality of care available to individuals affected by debilitating neurological and neuromuscular diseases.
GRIN Therapeutics is a clinical-stage biotechnology company dedicated to developing precision therapeutics for serious pediatric neurodevelopmental disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.